ASH 2018 Annual Meeting Highlights in Acute Myeloid Leukemia
Please complete Pre-test
Chapter 1 of 6
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, view video highlights from the 2018 American Society of Hematology (ASH) Annual Meeting
and listen as experts share their insights on a variety of abstracts, covering topics including, but not limited to: the efficacy and safety of emerging drugs for relapsed/refractory AML; venetoclax in combination for older AML patients who are ineligible for intensive chemotherapy; and the status of various clinical trials.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with acute myeloid leukemia (AML)
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in AML
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in AML
Chapter 1: Improving Outcomes in R/R AML: Can Unique Combinations of Novel Agents Impact Prognosis? Early Trial Results of Venetoclax + Idasanutlin and Azacitidine + Nivolumab, Azacitidine + Ipilimumab – Naval Daver, MD
Chapter 2: Maximizing Efficacy Across the Spectrum of AML: Early Clinical Trial Results of the FLT3 Inhibitor Quizartinib in Newly Diagnosed and R/R AML – Mark J. Levis, MD, PhD
Chapter 3: The Clinical Challenge of Older AML Patients Ineligible for Intensive Chemotherapy: Clinical Trial Results of Venetoclax in Combination with Cytarabine and HMAs – Daniel A. Pollyea, MD
Chapter 4: The Emerging Role of Bispecific Antibodies in AML: Promising Early Trial Results – Farhad Ravandi, MD
Chapter 5: Ivosidenib and Enasidenib: Do These IDH Inhibitors Impact Survival in Newly Diagnosed AML Patients? – Eytan M. Stein, MD
Chapter 6: Newer Generation Antibody-Drug Conjugates: Is There a Future For Monotherapy and/or Combination Strategies with Oral Agents in AML? – Eunice S. Wang, MD
Instructions for Participation and Credit
This activity is eligible for credit through December 21, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Naval Daver, MD
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.
Mark J. Levis, MD, PhD
Professor of Oncology
Director, Adult Leukemia Service
Co-Director, Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dr. Mark Levis completed a baccalaureate in genetics at UC Berkeley, and is a graduate of the Medical Scientist Training Program from UC San Francisco. He completed his residency training in internal medicine and a fellowship in medical oncology at Johns Hopkins University. He is a Professor of Oncology and the Director of the Adult Leukemia Service and Co-Director of the Division of Hematologic Malignancies at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. His broad research goals are to identify and validate novel molecular therapeutic targets in hematopoietic malignancies. His research group is interested in the identification and pre-clinical development of novel targeted therapies, and, in particular, the translational step of this research by using correlative studies to incorporate these novel therapies into existing treatments. Currently, Dr. Levis is actively involved in the pre-clinical and clinical development of small molecule kinase inhibitors targeting signaling pathway in acute myeloid leukemia, with a particular focus on FLT3.
Daniel A. Pollyea, MD
Clinical Director of Leukemia Services
Associate Professor of Medicine
Division of Hematology
University of Colorado
Dr. Daniel Pollyea completed his medical training at the University of Chicago Pritzker School of Medicine and his residency training in internal medicine at the University of Chicago Hospitals. He served as Chief Medical Resident at Chicago’s Cook County Hospital and then went to Stanford University for his fellowship training in hematology and oncology, where he also earned a master’s degree in epidemiology. He is now an Associate Professor of Medicine at the University of Colorado in the Division of Hematology, where he also serves as the Clinical Director of Leukemia Services.
Dr. Pollyea’s research interests involve understanding the nature of leukemia stem cells, and finding ways to target them in clinical trials with novel therapies. He serves as principal investigator of multiple clinical trials, has received grant funding from the Leukemia and Lymphoma Society, and has published more than 60 peer-reviewed journal articles.
Farhad Ravandi, MD
Professor, Department of Leukemia
Division of Cancer Medicine
Chief, Section of Developmental Therapeutics
The University of Texas MD Anderson Cancer Center
Dr. Farhad Ravandi received his medical degree from St. Mary's Hospital Medical School/Imperial College, University of London. He completed clinical residencies in internal medicine at The University of Texas, and in hematology at Baylor College of Medicine. He also completed a clinical fellowship in hematology/oncology, and a fellowship in blood and marrow transplantation, hematology/stem cell transplantation at The University of Texas MD Anderson Cancer Center. Dr. Ravandi is a Professor in the Department of Leukemia, Division of Cancer Medicine, and Chief, Section of Developmental Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Ravandi holds board certification in internal medicine, medical oncology, and hematology. He is a member of the Southwest Oncology Group Leukemia Committee, the NCCN Acute Myeloid Leukemia Committee, the International Hairy Cell Leukemia Consortium, and the Cancer and Leukemia Group B Data Safety Monitoring Board. Dr. Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematologic malignancies, in particular leukemias. He has extensively published his clinical research results in the field of adult leukemias, with a focus on acute leukemias in numerous peer-reviewed publications, articles, editorials, abstracts, and books/book chapters.
Eytan M. Stein, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.
Eunice S. Wang, MD
Chief, Clinical Leukemia Service
Professor, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr. Eunice Wang earned her medical degree from the Keck (University of Southern California) School of Medicine. She completed her internship and residency in internal medicine at Yale-New Haven Hospital, followed by clinical and research fellowships in hematology-oncology at Memorial Sloan Kettering Cancer Center in New York. She is Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center, Buffalo, New York. She is also an Associate Professor in the Department of Medicine, School of Medicine of Biomedical Sciences at the State University of New York at Buffalo (SUNY-UB).
Dr. Wang is a member of several professional organizations including the American Society of Hematology and the American Society of Clinical Oncology. She serves on the National Comprehensive Cancer Network (NCCN) Clinical Practice treatment guidelines panels for acute myeloid and acute lymphocytic leukemia. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award (CCITLA) and a Mentored Research Scholar award from the American Cancer Society. Dr. Wang has authored/co-authored more than 90 peer-reviewed articles in the field of hematological malignancies. She maintains an active clinical practice with a portfolio of early phase clinical trials in acute leukemias and myeloid malignancies. She also leads a translational laboratory focused on preclinical studies of novel agents targeting the marrow microenvironment and immune responses.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc. Celgene Corporation, Daiichi Sankyo, Inc., Helsin Healthcare SA.
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-053-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-053-091
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Otsuka Pharmaceutical Co., Ltd., Novartis AG, Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.
Dr. Mark Levis has received honoraria as a consultant from Agios, Astellas Pharma US, Inc., Daiichi Sankyo, Inc., Fujifilm Corporation, and Novartis AG. He has received grant support related to research activities from Astellas, Fujifilm, and Novartis.
Dr. Daniel Pollyea has received honoraria as a consultant from AbbVie Inc., Agios, argenx, Astellas Pharma US, Inc., Celgene Corporation, Celyad, Gilead, and Pfizer Inc. He has received grant support related to research activities from AbbVie Inc. and Pfizer Inc.
Dr. Farhad Ravandi has received honoraria related to formal advisory activities and grant support related to research activities from Amgen Inc., Seattle Genetics, Inc., Sunesis Pharmaceuticals, Inc., and Xencor, in addition to grant support related to research activities from Bristol-Myers Squibb Company and Selvita.
Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios, Astellas Pharma US, Inc., Bayer AG, Celgene Corporation, Daiichi Sankyo, Inc., Novartis AG, and Pfizer Inc.
Dr. Eunice Wang has received honoraria as a consultant from AbbVie Inc., Agios, Amgen Inc., Arog Pharmaceuticals, Inc., Celyad, Daiichi Sankyo, Inc., ImmunoGen, Inc., Jazz Pharmaceuticals plc, and Pfizer Inc., as well as speakers’ bureau activities from Astellas Pharma US, Inc., Jazz, and Novartis AG. She has received grant support related to research activities from ImmunoGen.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Improving Outcomes in R/R AML: Can Unique Combinations of Novel Agents Impact Prognosis? Early Trial Results of Venetoclax + Idasanutlin and Azacitidine + Nivolumab, Azacitidine + Ipilimumab – Run Time: 09:45
- Chapter 2: Maximizing Efficacy Across the Spectrum of AML: Early Clinical Trial Results of the FLT3 Inhibitor Quizartinib in Newly Diagnosed and R/R AML – Run Time: 06:33
- Chapter 3: The Clinical Challenge of Older AML Patients Ineligible for Intensive Chemotherapy: Clinical Trial Results of Venetoclax in Combination with Cytarabine and HMAs – Run Time: 04:41
- Chapter 4: The Emerging Role of Bispecific Antibodies in AML: Promising Early Trial Results – Run Time: 11:16
- Chapter 5: Ivosidenib and Enasidenib: Do These IDH Inhibitors Impact Survival in Newly Diagnosed AML Patients? – Run Time: 08:30
- Chapter 6: Newer Generation Antibody-Drug Conjugates: Is There a Future For Monotherapy and/or Combination Strategies with Oral Agents in AML? – Run Time: 07:50
- Assessment and Evaluation